{
  "id": 17973870,
  "title": "UniQure gets an FDA decision date; Teva scraps brain drug study",
  "url": "https://urgent.news/2026/11/03/uniqure-gets-an-fda-decision-date-teva-scraps-brain-drug-study",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-03T13:41:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/uniqure-fda-bright-minds-specific-teva-cinrock/873455/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}